Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 6 of the 20 sources its claims cite were checked for support.

Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey

Open access

Abstract

Background: Acute benzodiazepine withdrawal has been described, but literature regarding the benzodiazepine-induced neurological injury that may result in enduring symptoms and life consequences is scant. Objective: We conducted an internet survey of current and former benzodiazepine users and asked about their symptoms and adverse life events attributed to benzodiazepine use. Methods: This is a secondary analysis of the largest survey ever conducted with 1,207 benzodiazepine users from benzodiazepine support groups and health/wellness sites who completed the survey. Respondents included those still taking benzodiazepines (n = 136), tapering (n = 294), or fully discontinued (n = 763). Results: The survey asked about 23 specific symptoms and more than half of the respondents who experienced low energy, distractedness, memory loss, nervousness, anxiety, and other symptoms stated that these symptoms lasted a year or longer. These symptoms were often reported as de novo and distinct from the symptoms for which the benzodiazepines were originally prescribed. A subset of respondents stated that symptoms persisted even after benzodiazepines had been discontinued for a year or more. Adverse life consequences were reported by many respondents as well. Limitations: This was a self-selected internet survey with no control group. No independent psychiatric diagnoses could be made in participants. Conclusions: Many prolonged symptoms subsequent to benzodiazepine use and discontinuation (benzodiazepine-induced neurological dysfunction) have been shown in a large survey of benzodiazepine users. Benzodiazepine-induced neurological dysfunction (BIND) has been proposed as a term to describe symptoms and associated adverse life consequences that may emerge during benzodiazepine use, tapering, and continue after benzodiazepine discontinuation. Not all people who take benzodiazepines will develop BIND and risk factors for BIND remain to be elucidated. Further pathogenic and clinical study of BIND is needed.

Overview

CoChat Summary

TL;DR

This secondary analysis of the largest internet survey of benzodiazepine users reports that many respondents experienced prolonged symptoms, often lasting a year or longer, and adverse life consequences attributed to benzodiazepine use, tapering, or discontinuation. The authors propose the term benzodiazepine-induced neurological dysfunction (BIND) for this constellation of enduring symptoms and life consequences.

Key findings

  • Among 1,207 respondents, 88.1% reported anxiety, nervousness, or fear; 86.9% sleep disturbances; 86.2% low energy; and 85.3% difficulty focusing or distractedness. Overall, 76.6% of affirmative symptom answers reported durations of months or “one year or longer.”
  • Of those reporting specific symptoms, over half said the symptom lasted ≥1 year: low energy 59.9%, difficulty focusing/distractedness 58.3%, memory loss 57.5%, nervous/anxiety 57.0%, sleep disturbances 56.4%, sensitivity to sights and sounds 54.3%, digestive issues 52.2%, symptoms triggered by food or drink 52.0%, muscle weakness 51.2%, and body aches/pains 50.7%.
  • Many symptoms were reported as not matching the original prescription reason: restlessness 95.3%, muscle spasms 88.8%, pain/nerve spasms 88.1%, digestive/stomach/gut issues 75.8%, insomnia 57.5%, and situational anxiety/anxiety 55.6%.
  • Over 90% attributed one or more general adverse life consequences to benzodiazepine use; respondents averaged 8.1 of 16 adverse life consequences. Specific consequences included significantly affected marriage/other relationships 56.8%, suicidal thoughts or attempted suicide 54.4%, lost a job/fired/unable to work 46.8%, and lost savings or retirement funds 26.7%. Among 426 respondents off benzodiazepines for ≥1 year, 55.9% to 83.6% rated life consequences as severe or worse.

Methods

  • Secondary analysis of an internet survey of 1,207 current and former benzodiazepine users recruited through benzodiazepine support groups and health/wellness sites; respondents were taking full-dose benzodiazepines (n=136), tapering (n=294), or fully discontinued (n=763).
  • The survey asked about 23 symptoms, their duration, original prescription reasons, and adverse life consequences; questions and multiple-choice answers were derived from a subset of benzodiazepine-associated symptoms reported by Ashton and Wright.
  • Initial results were produced with SAS; subsequent analysis used a custom SQL Server data model and customized queries to examine correlations among prescription reasons, protracted symptoms, and adverse life consequences.

Limitations

  • Stated: self-selected internet survey with no control group; no independent psychiatric diagnoses could be made; recruitment primarily through benzodiazepine support group websites may not represent all benzodiazepine users; anonymous survey with no access to medical records to confirm benzodiazepine use or status; multiple-choice format; symptoms were a subset and may not reflect the complete range; no exclusion criteria for old age, comorbidities, or substance use disorder; respondents were not asked about other sedating or non-benzodiazepine hypnotic drugs; no baseline symptom comparison across the benzodiazepine use trajectory.
  • Evident: cross-sectional, self-reported attribution cannot establish causality between benzodiazepine use and symptoms or life consequences; support-group recruitment likely selects for more severe or distressing experiences; the paper notes statistical correlations between specific life consequences and symptoms could not be drawn.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0285584

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

6 Valid · 1 Not valid · 6 Not checked · 44 Own results and interpretations

20 more claims

Create a free account to see all 57 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 24
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Food and Drug Administration. Integrated drug utilization, epidemiology, and pharmacovigilance review: Benzodiazepine use, misuse, abuse, dependence, withdrawal, morbidity, and mortality Rockville, Maryland: Food and Drug Administration; 2020 [Available from: https://www.benzoinfo.com/wp-content/uploads/2020/11/Benzodiazepine-Information-Coalition-FOIA-FDA-.pdf/.

Cited by

See all 38

Metadata

Authors
Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R.
Affiliations
  • University of Colorado Anschutz (US)
  • Vanderbilt University Medical Center (US)
Corresponding author
Ritvo, Alexis D.
Venue
PLOS ONE
Published
2023-06-29
Volume
18
Issue
6
Pages
e0285584
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4382599949
Cited by
38
References
29
Citations by year
2026: 11 · 2025: 15 · 2024: 10 · 2023: 2
FWCI
7.55
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Brigham and Women's Hospital
  • Kaiser Permanente
  • Tulane University
  • University of South Carolina
  • Trinity College Dublin
  • Griffith University
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
benzodiazepine withdrawal, benzodiazepine tapering, benzodiazepine discontinuation, memory loss, anxiety, low energy
MeSH terms
Amnesia, Anxiety, Anxiety Disorders, Benzodiazepines, Humans, Control Groups

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. https://app.cochat.ai/papers/10.1371/journal.pone.0285584
The paper
Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023). Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PLOS ONE. https://doi.org/10.1371/journal.pone.0285584

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.